BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...

How practical is this form of pricing in the pharma setting? Reintroduction of the MFN model. The Trump Administration has revived the most-favored nation (MFN) drug pricing model as a seven-year test ...

The trend is continuing for brands and even for some specialty products. Thanks to the reemergence of cash pharmacy, the two primary funding sources for medications in the US—patients and plan ...

Acting commissioner Kyle Diamantas assumes interim control, prolonging uncertainty until a Senate-confirmed commissioner is installed and governance stabilizes. Elevated leadership churn and perceived ...

The pharmaceutical supply chain is rapidly entering its “AI-first” phase. Control towers predict delays, reroute shipments, ...

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle. In the second part of Pharmaceutical Commerce’s conversation with Tommy Bramley, ...

Sources familiar with White House deliberations suggest Makary’s departure is imminent, though neither the White House nor HHS has confirmed or named a successor. Makary’s tenure aligned FDA with MAHA ...

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Live from Asembia AXS26, Kim Plesnarski shares what a best-in-class reimbursement and support model looks like. In the second part of her conversation with Pharmaceutical Commerce at Asembia AXS26, ...

President Trump’s Most Favored Nation (MFN) drug pricing proposals are awaiting approval by the U.S. Congress. Passage of the “Generous,” Globe” and “Guard” proposals with MFN implementation for ...